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Genome-wide methylation analysis identiﬁes genes silenced
in non-seminoma cell lines
Dzul Azri Mohamed Noor1,2,6, Jennie N Jeyapalan1,3,6, Saﬁah Alhazmi1,4,6, Matthew Carr1, Benjamin Squibb1, Claire Wallace1,
Christopher Tan1, Martin Cusack1, Jaime Hughes1, Tom Reader1, Janet Shipley5, Denise Sheer3 and Paul J Scotting1
Silencing of genes by DNA methylation is a common phenomenon in many types of cancer. However, the genome-wide effect of
DNA methylation on gene expression has been analysed in relatively few cancers. Germ cell tumours (GCTs) are a complex group
of malignancies. They are unique in developing from a pluripotent progenitor cell. Previous analyses have suggested that
non-seminomas exhibit much higher levels of DNA methylation than seminomas. The genomic targets that are methylated, the
extent to which this results in gene silencing and the identity of the silenced genes most likely to play a role in the tumours’ biology
have not yet been established. In this study, genome-wide methylation and expression analysis of GCT cell lines was combined with
gene expression data from primary tumours to address this question. Genome methylation was analysed using the Illumina
inﬁnium HumanMethylome450 bead chip system and gene expression was analysed using Affymetrix GeneChip Human Genome
U133 Plus 2.0 arrays. Regulation by methylation was conﬁrmed by demethylation using 5-aza-2-deoxycytidine and reverse
transcription–quantitative PCR. Large differences in the level of methylation of the CpG islands of individual genes between tumour
cell lines correlated well with differential gene expression. Treatment of non-seminoma cells with 5-aza-2-deoxycytidine veriﬁed
that methylation of all genes tested played a role in their silencing in yolk sac tumour cells and many of these genes were also
differentially expressed in primary tumours. Genes silenced by methylation in the various GCT cell lines were identiﬁed. Several
pluripotency-associated genes were identiﬁed as a major functional group of silenced genes.
npj Genomic Medicine (2015) 1, 15009; doi:10.1038/npjgenmed.2015.9; published online 13 January 2016
INTRODUCTION
Promoter hypermethylation of many different tumour suppressor
genes is seen in a wide range of cancers.1,2 This has been
assumed, though only occasionally demonstrated, to silence the
expression of those genes. The term ‘methylator phenotype’
or CpG island methylator phenotype has been coined to
describe subgroups of cancers, such as some colon tumours and
gliomas, that exhibit particularly high levels of methylation of a
consistent subset of genes, usually in and around their CpG
islands.3–7
Testicular germ cell tumours (TGCTs) are the most common
malignancy of young men. Despite high cure rates in response to
platinum-based chemotherapy, they still represent a fatal disease
in a minority of patients presenting with disseminated disease8,9
and the prognosis in children is much worse than in adults.10 GCTs
are an exceptional group of tumours in many respects. They are
the only class of cancer that arises from a pluripotent progenitor
cell (the germ cell progenitor, PGC) and that cell exhibits
profoundly different DNA methylation characteristics to all
somatic cell types. They present as several remarkably varied
histological phenotypes classiﬁed as seminomatous or non-
seminomatous. Seminomatous tumours (called seminomas in
the testes, dysgerminomas in the ovary and germinomas in
extragonadal sites) exhibit a relatively uniform histology with a
similarity to germ cell progenitors. Non-seminomatous tumours,
such as yolk sac tumours (YSTs) and embryonal carcinomas (EC),
tend to be more aggressive and resistant to therapy than
seminomatous tumours,8,9,11 especially in intracranial cases seen
in children.10
Despite frequently having already metastasised at presentation,
most TGCTs are exceptionally chemosensitive. Their progression
from Intratubular Germ Cell Neoplasia, Unspeciﬁed (ICGNU) gives
rise to seminoma or to the various non-seminomas. The more
aggressive and chemoresistant non-seminomas can arise from
seminoma, even within the same tumour12 or as a recurrence after
treatment.13 There is some evidence that progression to non-
seminomas involves a dramatic increase in DNA methylation.14,15
Since all forms of GCT are believed to progress from ICGNU, which,
like germ cell progenitors, is hypomethylated, methylation must
be an event associated with their progression rather than tumour
initiation.16
Two recent studies of the global methylation of paediatric
GCTs demonstrated the hypermethylation of many candidate
tumour suppressor genes.14,15 Although these showed a dramatic
difference in methylation between GCT subtypes, with seminomas
showing much less methylation than non-seminomas, they could
not identify, in an unbiased manner, those genes that were
silenced by methylation. A critical question, therefore, is the extent
to which methylation is linked to gene silencing and how the
position of that methylation within the genes relates to this.
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In this study, we set out to analyse the relationship between
DNA methylation of different genes and gene elements and
consequent gene silencing. For this purpose, we needed to rely on
cell lines because they provide a more homogenous system
(as compared with the heterogeneity of primary tumour samples)
and where the causative role of DNA methylation in gene
silencing can be tested. Two recent studies have been published
that analysed global DNA methylation in GCT cell lines.
Rijlarsdaam et al.17 analysed methylation in cell lines derived
from multiple types of GCT but they did not determine the
relationship of this methylation to gene expression, while van der
Zwan et al.18 analysed both methylation and gene expression, but
only in seminoma versus EC cell lines. Here, the Illumina inﬁnium
HumanMethylome450 bead chip system, which surveys over 99%
of RefSeq genes with an average of 17 CpG sites per gene was
used. To gain a comprehensive view of the correlation between
methylation and gene expression, these same cell lines were
analysed using Affymetrix expression arrays. Finally, key genes
identiﬁed were tested to determine if they were activated by
demethylation, conﬁrming that DNA methylation was indeed
playing a role in their reduced expression. These data were also
compared with gene expression in a cohort of primary GCT
samples using the same array platform. These data conﬁrm that
the cell lines derived from different histological subtypes of
non-seminoma exhibit much greater gene-associated methylation
than the seminoma cells and identify a group of pluripotency-
associated genes, which are silenced in the YST as compared with
the seminoma cell line.
RESULTS
Relationships between genes methylated in different GCT
subtypes
DNA methylation was analysed in four adult GCT-derived cell lines
(TCam-2, GCT44, GCT27 and NT2D1, subsequently referred to as
Seminoma, YST, EC and Teratoma cell lines, respectively) on a
genome-wide scale using the Inﬁnium HumanMethylome450
array chip (University of London, London, UK; See Supple-
mentary Dataset 1 and 2). In all cell lines, the lowest level of
methylation was concentrated in CpG islands (Figure 1).
All three non-seminoma cell lines showed higher numbers of
methylated island CpGs (β-value ⩾ 0.6) than the seminoma cell
line. For the EC and teratoma cell lines, a similar degree of
difference to seminoma was also seen in all other regions (shores,
shelves and ‘open sea’), whereas for the YST cells this difference
decreased in the shores and the number of methylated CpGs in
shelves and open sea was lower than that in the seminoma cells
where many more were unmethylated (β-value o0.3) (Figure 1).
We next set out to identify the speciﬁc genes where CpG islands
were differentially methylated between seminoma and non-
seminoma cell lines. We chose to initially select those genes that
were methylated across CpG islands near to the TSS (CpG islands
exhibiting an average methylation β-value ⩾ 0.6 were recorded as
methylated). This analysis showed that the EC cell line had the
highest number of genes with TSS-associated methylated CpG
islands, followed by YST, teratoma and seminoma cells (Figure 2a).
To establish similarities and differences between the cell lines,
the overlap in the lists of genes methylated in each cell type were
identiﬁed (Figure 2b). Genes methylated in seminoma cells are
largely a subset of those methylated in EC and teratoma cells.
Indeed, 94% of genes (337/358) methylated in the seminoma cell
line are also methylated in EC and/or teratoma cells with 62% of
these genes being methylated in all three non-seminoma
subtypes (Figure 2b). The population of genes methylated in the
YST cell line appears to be more strikingly different. The YST cell
line exhibited the highest number of uniquely methylated genes
relative to the total number of methylated genes (270/806,
Figure 2b). By comparison, only 16 genes were methylated
uniquely in the seminoma cell line.
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Figure 1. Percentage of CpGs methylated (β-value ⩾ 0.6) described
relative to CpG islands. The 450 K arrays provide a quantitative
reading (β-value) from 0 (unmethylated) to 1 (completely
methylated) for individual CpG sites, each described in relation to
the closest gene and the nearest CpG island. These are annotated
as island (a region of at least 500 bp, with 455% GC and an
observed-to-expected CpG ratio 40.65), shore (regions 2 kb either
side of an island), shelf (regions 2 kb outside of the shores) or ‘other’,
also referred to as ‘open sea’.
Figure 2. Gene methylation based on average methylation across CpG islands in the TSS region. A gene was considered to be methylated
when the average β-value across all CpGs analysed in CpG island(s) located near to the gene’s TSS (within 1,500 bp upstream of the TSS or
within the 5′ UTR/ﬁrst exon) was 40.6. (a) Number of genes methylated (average β-value ⩾ 0.6) is represented as a percentage of all genes
associated with a CpG island. Values above bars indicate number of gene. (b) Venn diagram representing the overlap between genes
methylated in each cell line. The gene count of each section is indicated.
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Transcriptome analysis reveals that over 50% of differentially
methylated genes show a corresponding difference in gene
expression
The best-documented mechanism for a gene methylation event to
contribute to the biology of a cell is through altering that gene’s
expression. We therefore set out to determine to what extent the
gene methylation events described above were reﬂected in
silencing of these genes.
RNA was isolated from each of the cell lines and subjected to
gene expression analysis using Affymetrix U133 plus 2 chips (the
University of Nottingham, Nottingham, UK; See Supplementary
Dataset 3). The data were analysed to assess the relationship
between CpG methylation and gene expression. In particular, we
asked if high methylation correlated with low expression
(see Supplementary Dataset 4). The degree of correlation between
the level of differential methylation of the various gene elements
(regarding islands, shores or shelves) and inverse gene expression
was analysed pairwise between cell lines. We divided gene
elements into categories of differential methylation at average Δβ
intervals of 0.05 across those elements (see Table 1). The lowest
category (Δβ=0 to 0.05) corresponds to a large group of genes,
which showed similar levels of methylation in seminoma and
non-seminoma lines, while the highest category (Δβ=0.9 to 0.95)
corresponds to genes that showed the greatest increase in
methylation in the seminoma line relative to non-seminoma lines.
For each category, we calculated the expected frequency of genes
showing more than twofold differential expression under the null
hypothesis that lower gene expression does not correlate with
methylation. For each category of methylation, we then applied a
Pearson’s Χ2-test to determine whether the observed frequency of
differential expressed genes was greater than expected by chance.
The aim of this approach was to provide us with an objective basis
for the selection of genes where a correlation between differential
methylation and differential expression was likely to be of biological
signiﬁcance. The resulting data (for CpG islands comparing the
non-seminoma and seminoma cell lines) are shown in Table 1.
These data were then used to generate graphs showing the
percentage of genes with more than twofold differential expression
for each Δβ-value category (Figure 3, Supplementary Figure S1).
Comparing the YST and seminoma cell lines, there was a
substantial (greater than two times the value expected at random)
and signiﬁcant correlation between lower expression in YST cells
and a difference in methylation 40.65 Δβ-value (Figure 3a). For
this reason, all further analyses excluded genes that were
differentially expressed but where differential methylation was
o0.65, since for any given gene a correlation with a lower level of
differential methylation is more likely to simply reﬂect a random
association. Similar comparison of EC and teratoma cell lines to
the seminoma cell line found that a signiﬁcant and substantial
association between methylation and silencing of expression was
reached at an average Δβ-value of over 0.7 (Figures 3b,c). For all
non-seminoma cell lines, islands showed a stronger correlation
with reduced expression than methylation of shores or any other
regions (Figure 3, Supplementary Figure S1).
Based on the Δβ-value thresholds established above those
genes expressed in seminoma but not in the non-seminoma cell
lines, where reciprocal differential methylation of CpG island near
the TSS was implicated in their silencing in non-seminoma cells,
were identiﬁed (Figures 3 and 4a). Among genes differentially
methylated at a TSS-associated CpG island between non-
seminoma and seminoma cell lines (for which expression data
were available) about half showed a correlating decreased
expression in the various non-seminoma cell lines. It was notable
that the genes identiﬁed in this way feature high among the most
differentially expressed genes between seminoma and the various
non-seminoma cell lines. Of the top 10 most differentially
expressed genes (for which we have methylation data) in the
non-seminomas, 4 are differentially methylated in EC cells, 3 in
YSTs and 2 in teratoma cells. Thus it seems that differential
methylation could play a substantial role in the differential gene
expression between seminoma and non-seminoma cells.
Strong correlation between methylation of islands in gene bodies
and gene silencing
In previous studies, methylation in gene bodies has been
associated with active genes.19,20 However, using the same cut-
off of 0.65 Δβ-value for differential methylation and a twofold
difference in gene expression described above, we found that
increased methylation in body CpG islands was more strongly
associated with gene silencing than activation (Figure 4b). In the
YST cells line, 45 out of 128 genes exhibiting increased
methylation of body CpG islands compared with the seminoma
cells showed a correlating twofold or greater decrease in
expression and were only rarely associated with gene activation
(Figure 4b). A similar relationship was seen in the EC and teratoma
cells (Figure 4b). Although many of these genes also exhibited
methylation of a CpG island in the region of the promoter, even
for genes with a TSS-associated CpG island that was not
differentially methylated, the body CpG island methylation was
still more strongly associated with silent rather than active genes
(Figure 4b). In total, 34 genes for which body CpG island
methylation correlated with silencing of expression either lacked
a promoter-associated island or these other islands were not
differentially methylated. These genes were therefore included in
subsequent analysis (asterisk in Tables in Figure 4a).
Validation of genes silenced by methylation
The expression of a subset of the above genes was assessed using
reverse transcription–PCR (RT–PCR). This conﬁrmed the results of
the Affymetrix expression arrays for all 17 genes analysed (Figure 5
and see Supplementary Figure S2). The positions of all the CpGs
analysed within each gene were also characterized with reference
to the gene structure and all CpGs within the gene (some of which
were not included on the methylation array). This veriﬁed that in
these 17 genes, the differences in average methylation across
CpGs annotated as islands did reﬂect multiple CpGs and that
these differences were quite consistent across the whole or large
parts of each of those islands.
A particular reason for using cell lines in this study was that it
allowed us to conﬁrm the role of DNA methylation in regulating
expression of the genes identiﬁed. We therefore tested whether
these genes would be re-expressed if demethylated. YST cells
were treated for 2 days with 5-aza-2-deoxycytidine and then
expression of ﬁve of the same 17 genes was reexamined by
RT–PCR and RT–quantitative PCR (RT–qPCR). This showed that all
ﬁve genes were activated by 5-aza-2-deoxycytidine (Figure 6).
Aberrant gene methylation most likely represents gain of
methylation in non-seminoma cells
To determine which methylation events in the cell lines were likely
to be aberrant cancer-related events, methylation of the key genes
identiﬁed above (Figure 4) was compared with a series of control
sets of Inﬁnium HumanMethylome450 array methylation data
from normal tissues (See Supplementary Dataset 5).
Almost all of the genes identiﬁed as methylated in non-
seminoma cell lines but unmethylated in seminoma cells were
also unmethylated in all control samples. Two striking exceptions
to this were the genes DDX43 and TDRD12. DDX43 was heavily
methylated in all samples other than seminoma while TDRD12
was methylated in all samples except seminoma and teratoma.
Hence, the heavy methylation of these two genes in all control
samples implies the difference between GCTs is due to unusual
hypomethylation in seminoma (and teratoma for TDRD12).
Genome-wide methylation analysis of GCT cell lines
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Table 1. Contingency tables of observed and expected number of genes differentially expressed (correlating and anti-correlating), and genes with
no difference in expression for ranges of differential methylation between non-seminoma and seminoma cell lines
Δβ SEM/YST No difference
Observed
No difference
Expected
YST/SEM Total P value Signiﬁcance
Genes 42-fold Genes 42-fold Genes 42-fold Genes 42-fold Χ2 (2df)
Observed Expected Observed Expected
0.9–0.95 2 0.75 2 2.86 0 0.39 4 0.2537
0.85–0.9 3 1.31 4 5.01 0 0.68 7 0.2157
0.8–0.85 16 5.42 10 20.75 3 2.82 29 0 ***
0.75–0.8 16 4.86 8 18.6 2 2.53 26 0 ***
0.7–0.75 16 5.61 9 21.47 5 2.92 30 0 ***
0.65–0.7 11 5.42 16 20.75 2 2.82 29 2.93E− 02 *
0.6–0.65 12 6.55 21 25.04 2 3.41 35 5.57E− 02
0.55–0.6 7 5.05 17 19.32 3 2.63 27 0.5819
0.5–0.55 13 7.67 26 29.34 2 3.99 41 0.0789
0.45–0.5 15 9.17 30 35.06 4 4.77 49 0.1018
0.4–0.45 21 10.66 29 40.79 7 5.55 57 0.001 ***
0.35–0.4 16 13.66 49 52.23 8 7.11 73 0.6998
0.3–0.35 29 16.46 47 62.97 12 8.57 88 0.0006 ***
0.25–0.3 29 20.02 64 76.56 14 10.42 107 0.0257 *
0.2–0.25 40 28.43 90 108.76 22 14.81 152 0.0033 **
0.15–0.2 34 34.98 128 133.8 25 18.22 187 0.2458
0.1–0.15 57 50.88 185 194.62 30 26.49 272 0.4326
0.05–0.1 96 78.57 279 300.52 45 40.91 420 0.0545
0–0.05 339 466.53 1,939 1,784.54 216 242.93 2,494 0.00E+00 ***
Total 772 772 2,953 2,953 402 402 4,127
Δβ SEM/TERT No difference
Observed
No difference
Expected
TERT/SEM Total P value Signiﬁcance
Genes 42-fold Genes 42-fold Genes 42-fold Genes 42-fold Χ2 (2df)
Observed Expected Observed Expected
0.9–0.95 0 0 0 0 0 0 0 0
0.85–0.9 2 0.72 2 2.83 0 0.45 4 0.2225
0.8–0.85 6 2.5 8 9.9 0 1.58 14 0.0327 *
0.75–0.8 7 1.61 2 6.37 0 1.02 9 0.00001 ***
0.7–0.75 4 1.07 2 4.25 0 0.68 6 0.0072 **
0.65–0.7 6 3.04 9 12.03 2 1.93 17 1.61E− 01
0.6–0.65 6 3.39 11 13.45 2 2.16 19 2.94E− 01
0.55–0.6 3 3.22 12 12.74 3 2.04 18 0.776
0.5–0.55 6 4.11 14 16.28 3 2.61 23 0.537
0.45–0.5 6 4.47 17 17.69 2 2.84 25 0.6713
0.4–0.45 5 4.65 19 18.4 2 2.95 26 0.8387
0.35–0.4 8 4.83 14 19.11 5 3.06 27 0.0965
0.3–0.35 9 6.08 18 24.06 7 3.86 34 0.0642
0.25–0.3 9 10.55 40 41.76 10 6.69 59 0.38001
0.2–0.25 19 17.17 58 67.94 19 10.89 96 0.0214 *
0.15–0.2 30 24.49 90 96.96 17 15.54 137 0.3921
0.1–0.15 33 42.38 172 167.73 32 26.89 237 0.2064
0.05–0.1 72 71.7 279 283.8 50 45.49 401 0.7676
0–0.05 245 270.01 1,117 1,068.69 148 171.31 1510 0.0216 *
Total 476 476 1,884 1,884 302 302 2,662
Δβ SEM/EC No difference
Observed
No difference
Expected
EC/SEM Total P value Signiﬁcance
Genes 42-fold Genes 42-fold Genes 42-fold Genes 42-fold Χ2 (2df)
Observed Expected Observed Expected
0.9–0.95 0 0 0 0 0 0 0 0
0.85–0.9 2 0.29 0 1.5 0 0.19 2 0.0031 **
0.8–0.85 10 2.51 7 12.79 0 1.69 17 1.60E− 06 ***
0.75–0.8 11 2.66 7 13.54 0 1.79 18 1.76E− 07 ***
0.7–0.75 11 3.25 10 16.55 1 2.19 22 0.00002 ***
0.65–0.7 7 4.14 17 21.07 4 2.79 28 0.1935
0.6–0.65 5 3.55 17 18.06 2 2.39 24 6.97E− 01
0.55–0.6 6 4.73 23 24.08 3 3.19 32 0.8183
0.5–0.55 11 6.06 29 30.85 1 4.09 41 0.0393 *
0.45–0.5 6 4.88 20 24.83 7 3.29 33 0.0682
0.4–0.45 7 5.32 26 27.09 3 3.59 36 0.7149
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Comparison of two data sets comparing seminoma to EC cell lines
Van der Zwan et al.18 recently using the same 450k methylation
chips and Affymetrix expression platforms to compare the same
seminoma cell line (TCam-2) with a different EC cell line (NCCIT).18
We reanalysed the data of van der Zwan et al.18 using the same
pipeline described above (see Supplementary Datasets 6 and 7;
S3 and 4 Tables). Strikingly, 63% of the genes that were
differentially methylated in the study of van der Zwan et al.18
were also differentially methylated in our study; 59% of the
differentially expressed genes were shared, and of the 7 genes
that were both differentially methylated and differentially
expressed (with the methylation correlating with gene silencing)
3 of these (HSPA2, PON3 and TACSTD2) were among the 43 genes
in this category in our study. These correlations are highly
signiﬁcant (binomial test Po1 × 10− 7). These data show that
the gene methylation and expression events are remarkably
consistent between independent EC cell lines.
Identiﬁcation of genes for which methylation is most likely to be
of biological signiﬁcance
To determine if the differences in expression between seminoma
and non-seminoma cell lines might be a more general feature of
GCTs, we made use of the Affymetrix expression data of Korkola
et al.21 from a cohort of adult TGCTs and Palmer et al.22 from a
cohort of paediatric seminomas and YSTs from many different
anatomical locations. Although, such banks of tumour samples
would be expected to differ substantially from the gene
expression seen in the clonal cell lines used here, we reasoned
that genes identiﬁed by this comparison, where the role of these
genes might be conserved in many GCT samples analysed, would
be those events of greatest importance generally in GCT biology.
Comparing seminoma to YST samples, the overlap in genes
differentially expressed in these data sets was highly signiﬁcant
(Supplementary Figure S5). Among the genes represented in all
three studies, any 2 studies shared ~ 500–700 genes that were
differentially expressed and of these 339 genes were differentially
expressed in all 3datasets. Of the 72 genes shown to be both
differentially methylated and differentially expressed between the
YST and seminoma cell lines in this study (Figure 4), 23 were
expressed at higher levels in primary seminomatous tumours than
in YSTs (41.5-fold) in either the Palmer et al.22 or Korkola et al.21
data sets with 11 being differentially expressed in both studies
(Table 2A). Such a high proportion of differentially expressed
genes common to the cell lines and the primary tumours is highly
signiﬁcant (binomial test: Po10− 30) strongly suggesting that the
cell lines provide a good surrogate system for studying gene
expression in this tumour type. It is also striking that several of
these genes encode proteins that are involved in pluripotency
and the inhibition of differentiation (see Discussion below).
Comparison of the differentially expressed genes between our
data and that of Korkola, et al. 21 for EC and teratoma cell lines also
showed much weaker overlap of the genes differentially
expressed, although this was still signiﬁcant for the EC cell data.
However, it is noteworthy that three of the ﬁve genes methylated
and differentially expressed in all three non-seminoma cell lines
(DDX43, PON3 and RBMXL2) were also differentially expressed in
all three tumour types in the data of Korkola et al.21 (Tables 2B,C).
DISCUSSION
This study describes the ﬁrst comprehensive analysis of global
methylation and its relationship to gene expression in cell lines of
the major subtypes of GCTs. Of the 7,244 genes that produced
reliable signals in the expression array dataset, ~ 2% (147) of the
genes showed correlating differential methylation and expression
in our data, of which we were able to identify 23 genes with
similar differential expression in cohorts of primary tumour
samples.
Global differences in methylation between GCT cell lines
This study conﬁrms the suggestion from analysis of fewer genes
that non-seminoma cells exhibit very high levels of gene
methylation as compared with seminoma cells, which exhibit a
strikingly low level of gene methylation.14,15
As found in other classes of cancer, the hypermethylation we
see in the YST as compared with seminoma cells is restricted to
the CpG islands of a relatively small proportion of genes,
a so-called CpG island methylator phenotype. Analysis of EC and
teratoma cells revealed a much less localised difference in
methylation. In these cells, the extent to which methylation of
CpGs was higher than in seminoma cells was almost uniform
across CpGs in all regions. This hypermethylation does not,
therefore, represent a CpG island methylator phenotype. This
implies a much less biologically regulated process than the
targeted methylation of CpG islands seen in YST cells. However,
despite the fact that the methylation did not appear to be
targeted to CpG islands in EC/teratoma cells, there was still a
strong inverse correlation between CpG island methylation and
the level of gene expression. Hence, regardless of the mechanism
that results in CpG island hypermethylation, such methylation
shows a strong correlation with gene silencing.
Table 1. (Continued )
Δβ SEM/EC No difference
Observed
No difference
Expected
EC/SEM Total P value Signiﬁcance
Genes 42-fold Genes 42-fold Genes 42-fold Genes 42-fold Χ2 (2df)
Observed Expected Observed Expected
0.35–0.4 5 6.06 33 30.85 3 4.09 41 0.7312
0.3–0.35 8 9.9 51 50.41 8 6.68 67 0.729
0.25–0.3 11 13.15 68 66.97 10 8.88 89 0.7749
0.2–0.25 21 16.7 74 85.02 18 11.27 113 0.0378 *
0.15–0.2 20 18.03 85 91.79 17 12.17 122 0.2681
0.1–0.15 32 32.96 169 167.79 22 22.25 223 0.9805
0.05–0.1 56 59.86 298 304.73 51 40.41 405 0.2045
0–0.05 288 322.94 1,698 1,644.06 199 218 2,185 0.0272 *
Total 517 517 2,632 2,632 349 349 3,498
Abbreviations: EC, embryonal carcinoma; df, degree of freedom; SEM, seminoma; TERT, teratoma; YST, yolk sac tumour. P values of the Χ2-test of association
between methylation and expression are given. *Po0.05
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CpG island methylation shows the strongest correlation with
reduced gene expression
Methylation of CpGs islands was more strongly correlated with
low gene expression than was methylation in other regions.
With respect to gene structure itself, most methylated islands
were in the region of gene promoters. However, some were in
the gene body where they similarly correlated with gene
silencing. Methylation of CpG islands in gene bodies has been
reported to be associated with active genes.23,24 Therefore, the
situation in GCT cell lines reveals a distinctly different
relationship. Recent studies have implicated a variety of
differentially methylated regions as most inﬂuential in the
regulation of gene expression. Kulis et al.25 found that in
differentiated B-cells and leukaemic cells differences in methyla-
tion in the gene bodies and promoter-associated CpGs
correlated with differences in gene expression, but the correla-
tion was stronger for gene bodies.25 In their study, as has been
found before, increased methylation in gene bodies correlated
more often with increased expression rather than decreased
expression, although numerous genes did exhibit the latter.
Figure 3. Correlation between differential expression of over twofold and different degrees of differential CpG island methylation between
seminoma and non-seminomas. Histograms showing the observed (blue) and expected (red) percentage correlation for each Δβ-value range
for TCAM2 (seminoma) versus GCT44 (YST) (a), GCT27 (EC) (b) and NT2D1 (teratoma) (c). A Δβ-value of 40.65 or 0.7 consistently correlated
signiﬁcantly with a difference in expression of greater than twofold. While some lower Δβ-value categories also show signiﬁcant association,
statistical signiﬁcance was reached at much smaller percentage levels of association due to a larger number of genes in those differential
methylation ranges (see Figure 2 for details) (for example, comparing GCT44 to TCAM2, 152 genes exhibit Δβ-values between 0.2–0.25 with
only 26% show a correlation with decreased expression (over a random expected association of 18%, but this achieves a P value o0.01).
On the other hand, due to the small numbers of genes exhibiting some of the highest differential methylation values, these were not
signiﬁcantly associated with differences in expression, often despite a large percentage levels of association (for example, comparing GCT44
to TCAM2, seven genes exhibit a Δβ-values between 0.85 and 0.9 of which three (43%) show a correlation with decreased expression, but this
does not achieve a signiﬁcant P value). Signiﬁcance of the Χ2-tests of association are shown (*Po0.05, **Po0.01, ***Po0.001) and the total
number of genes in each category is displayed above the bar.
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Irizarry et al.26 found that differences in methylation of CpG
shores correlated best with differences in gene expression in
both tissue-speciﬁc and cancer-speciﬁc differentially methylated
regions.26 More recently a whole genome bisulﬁte sequencing
study in medulloblastomas identiﬁed regions ~ 2 kb downstream
of the transcription start site as showing the strongest correlation
with gene expression.27 Hence, it seems that the role of
methylation of different gene regions in controlling gene
expression varies in different tissue types and different cancers.
It will be interesting in the future to ﬁnd whether the situation
seen in GCT cell lines is an unusual feature of their germ cell
lineage, or a more general phenomenon in a range of cancers.
DNA methylation and cancer progression in GCTs
Our ﬁnding that the non-seminoma cell lines exhibit very high
levels of gene methylation as compared with seminoma cells is
consistent with earlier, less comprehensive studies, which showed
that non-seminomas exhibit much higher levels of gene methyla-
tion than seminomas.14,15
Figure 4. Genes differentially methylated and differentially expressed between seminoma and non-seminoma cell lines. (a) Tables show genes
expressed at higher levels in seminoma than in non-seminoma cell lines (⩾2-fold difference in expression from microarray data), that are also
signiﬁcantly more methylated (Δβ ⩾ 0.7 for EC and teratoma, ⩾ 0.65 for YST) in the non-seminoma lines. Differential methylation was
associated with CpG islands near to a TSS, except for those genes marked with an asterisk where methylation was across CpG islands in the
body of the gene. These same genes are shown as numbers in the various overlapping cell types (colours match tables) in the central Venn
diagram. (b) Graph showing numbers of genes showing differential expression between seminoma and various non-seminoma cell lines
grouped according to exhibiting differential methylation in body and TSS regions (all genes included exhibit greater methylation (Δβ ⩾ 0.65)
in a non-seminoma versus the seminoma cell line across the island. Numbers above each bar indicate the number of genes that were
differentially methylated but showed less than a twofold difference in expression between the cell lines.
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In previous studies, using immunostaining, DNA methylation
was undetectable in ICGNU and most seminomas while strong
methylation was seen in non-seminomas.16,28 Even in mixed
tumours, seminoma elements were unmethylated and non-
seminoma components methylated.16 This led Netto et al.16 to
propose that ICGNUs are derived from PGCs at an embryonic
Figure 5. Graphical representation of selected methylated genes and validation of differential expression. For each gene, panels show (a) graph
of average methylation across CpG islands in the four cell lines, (b) level of expression from array analysis (‘Relative expression level (microarray
analysis)’ represents the signal relative to control probes), (c) RT–PCR analysis, (d) graph of CpG density across the gene structure (green bar
indicates position of the promoter) and (e) level of methylation at each CpG included in 450 K chips relative to CpG features in d. Promoter
prediction was achieved using the Eukaryotic Promoter Database (http://epd.vital-it.ch) for identiﬁcation of transcription start sites (TSSs)
together with a review of the literature for each gene; gene sequences were submitted to the MethPrimer programme (http://www.urogene.org/
methprimer/) to identify CpG sites and islands. Blue vertical bars represent CpG islands, red vertical bars below graphs represent CpG sites.
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stage when methylation has been erased, and seminomas
subsequently arise from ICGNU. Given that the seminoma cell
line, TCAM2, can give rise to tumours closely resembling EC in an
experimental in vivo context29 and tumours containing a mixture
of seminomatous and non-seminomatous components are not
uncommon, it seems possible that hypermethylation could
represent a progression event involving de novo methylation of
such seminomatous components. It therefore seems plausible that
pure non-seminomas could also arise by de novo methylation
from a non-methylated ICGNU or seminoma precursor lesion
that existed prior to diagnosis. This would be consistent with the
well-documented phenomenon of non-seminomas arising as
recurrences of seminomas.13
Cell lines as a useful system for methylation studies
As shown here, the correlation between substantial methylation of
CpG islands and gene silencing is well below 100%. It is therefore
critical that DNA methylation is not simply assumed to be the
cause of gene silencing. In this study, in addition to determining
the level of differential methylation that best correlated with gene
silencing, we were able to utilise these cell lines to verify the role
of methylation using the DNA-demethylating agent 5-aza-2-
deoxycytidine. To determine whether silencing of these genes
was a more general phenomenon in primary tumours, we showed
that there was a highly signiﬁcant overlap in the genes silenced by
methylation in the cell lines in this study and those genes that
differed in their expression in a cohort of paediatric GCT samples.
Although this does not determine if differences in expression in
the tumour samples are due to their methylation, it is the
difference in expression that is the biologically important outcome
of the methylation. Analysis of primary tumour samples using
lower coverage analyses has already shown the same general
differences in the level of methylation between seminoma and
non-seminoma tumours that we found in the corresponding cell
lines,14,15 supporting the hypothesis that the methylation seen in
the cell lines is a reﬂection of that seen in primary tumours.
Concerns have been raised over using cell lines for methylation
studies.30 Smiraglia et al.30 concluded that cancer cell lines
develop aberrant methylation proﬁles as an artifact of the culture
process.30 Although this possibility cannot be ruled out, this is not,
in our view, the only or indeed the most likely interpretation of the
data in their study. Smiraglia et al.30 showed, using restriction
landmark genomic scanning, that the high level of methylation
seen in some cancer cell lines was not reﬂected in primary
tumours of the same type (although not the actual tumour
samples from which those cell lines were derived). Their
conclusion is based on the assumption that the average
methylation state of all the cells in most of a given class of
tumour should be similar to that found in a cell line derived from
that tumour. However, an alternative explanation for their
observations, for which there is clear precedent, is that the cell
line methylation status reﬂects the minority population of tumour
cells from which the cell lines originate. These cells are a
proliferating subset of cells within the tumours, which could
represent the cancer stem cell/tumour initiating cell. Such a
difference in DNA methylation clearly exists in normal tissues of a
single individual in vivo that, like tumours, are genetically clonal.
This is true of different cell populations in the same tissue31,32 and
differentiated cells versus proliferating stem cells in whole
organisms.33 In such examples the gene methylation proﬁles of
genetically identical cells can be dramatically different in vivo, just
as the proﬁle of a cancer stem cell or cancer-derived cell line
might differ from less primitive proliferating cells or their more
differentiated progeny in the primary tumour.
Indeed, using a more sensitive analysis of cell lines and the
pancreatic cancers from which they were derived, Ueki et al.34
(using methylation-speciﬁc PCR) concluded that ‘most of the DNA
methylation of tumour suppressor genes observed in cancer cell
lines is present in the primary carcinoma from which they were
derived.34
Given our observations that the seminoma cell line exhibits no
apparent increase in methylation, that the hypermethylation we
identiﬁed in one EC cell line was very similar to that seen in a
different cell line in another study van der Zwan et al.18 and that
the overall pattern of methylation we found is consistent with
earlier studies of primary tumour samples, it seems likely that the
majority of methylation events we see reﬂect genuine differences
between these tumour types.
Several pluripotency regulators are silenced in non-seminoma cell
lines
Of the 108 genes silenced by methylation in the YST cell line,
21 were also similarly differentially expressed in primary tumour
samples (Table 2). Among these 21 genes several have previously
been associated with germ cell progenitors and/or pluripotency.
KLF4 is one of the four ‘Yamanaka’ factors that together can
endow somatic cells with the potential to adopt a pluripotent
embryonic stem cell-like state35 and is highly expressed in the
pluripotent progenitors of germ cells, the PGCs.36,37 Its suppres-
sion by methylation in non-seminomas might therefore play a key
role in their more differentiated and more aggressive state. It is
also noteworthy that Klf4 expression is affected by the protein
encoded by another silenced gene, Prdm1438 (discussed below)
and that silencing Tet1 in mice (which results in hypermethylation
of DNA) downregulates the expression of Klf4 and Prdm14.39
Therefore, silencing of these two genes may be intrinsically linked.
Figure 6. RT–PCR analysis of gene expression for selected genes in YSTs following treatment with 5-deoxyazacytidine. (a) Gel image showing
activation of ﬁve genes following treatment with 5-deoxyazacytidine as compared with control ACTB. (b) RT–qPCR data for the same
experiments. *P⩽ 0.01; **P⩽ 0.001.
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Table 2. List of the genes identiﬁed as differentially methylated and
differentially expressed between cell lines that were also differentially
expressed in the same way in primary seminoma and non-seminoma
tumour samples22
A. Seminoma versus YST
Gene Noor (2015) Korkola et al.21 Palmer et al.22
EPCAM 561.2 0.4 0.4
TACSTD2 448.8 0.1 0.9
GGCT 120.4 1.0 1.5
F2RL1 106.1 0.9 0.8
TDRD12 84.4 8.5 8.0
FABP5 65.7 1.4 0.5
HSPA2 50.7 0.9 0.9
SOX17 48.7 0.8 0.6
RBMXL2 43.5 2.3 1.4
BASP1 42.0 0.8 1.3
DDX43 37.3 3.6 3.9
KLF4 29.9 5.9 7.2
LGALS3 28.1 0.8 1.6
ESRP2 27.7 0.3 0.5
CYB5R2 18.2 1.1 1.0
OXCT1 17.2 1.2 1.9
HIST1H4C 17.1 1.5 0.9
CLDN7 15.2 0.4 0.2
ALDH1A3 14.6 1.4 0.4
ECHDC3 14.5 0.9 1.8
TRIL 14.4 1.9 1.4
TMEM168 14.2 1.4 2.2
CXCL14 13.0 2.7 5.1
DSCR6 10.2 0.5 0.2
GPX7 9.6 1.0 1.0
FAM184A 9.4 0.4 0.5
ECHDC2 9.2 0.5 0.9
IER2 9.0 1.0 1.5
GUCA1A 7.5 1.8 1.2
LGALS8 7.4 0.6 0.9
ST14 6.7 0.7 0.5
MAPK13 6.3 0.5 0.8
LMO7 6.2 0.6 0.8
OVOL1 6.2 0.8 0.8
LY75 6.0 3.5 3.4
CYB5R1 5.6 1.0 1.3
GIPC2 5.6 0.6 0.8
EPS8L2 5.5 0.4 0.4
CST6 4.8 0.8 1.2
PKP3 4.7 0.4 0.3
ALX1 4.6 1.0 0.8
PARP12 4.3 3.9 2.6
BST1 4.3 1.5 1.5
CYP1B1 4.3 1.0 1.8
MNS1 3.6 1.0 1.0
SOX15 3.5 5.9 3.3
MTL5 3.5 0.8 0.8
MYD88 3.3 1.0 0.9
PRDM14 3.2 1.6 1.2
MEIS1 3.2 0.5 0.4
TNFRSF10C 3.1 0.9 1.0
TRIM25 3.1 1.0 0.9
PON3 3.0 1.6 4.9
PLXND1 3.0 1.0 0.9
RPRM 3.0 2.3 2.4
LTBP2 2.9 1.1 0.6
FUT1 2.8 1.1 1.0
SLC25A38 2.8 0.8 0.8
EPS8L1 2.6 0.8 0.7
ARPC1B 2.6 2.3 2.9
EDNRB 2.6 0.9 0.9
TEAD3 2.5 0.6 0.7
ACADL 2.5 1.1 0.9
TUBB6 2.5 0.9 0.6
ZMIZ1 2.4 1.6 1.1
ABHD14A 2.2 0.8 0.9
ELMO3 2.2 0.8 0.7
AMPD3 2.1 1.1 1.3
LRRFIP1 2.0 1.3 1.2
ZIC1 2.0 0.5 0.7
SH2D3A 1.6 1.0 1.0
NAAA 1.5 1.1 1.1
Table 2. (Continued )
B. Seminoma versus EC
Gene Noor (2015) Korkola et al.21
TACSTD2 322.3 0.3
NUDT15 96.1 0.6
RBMXL2 52.8 1.6
HSPA2 35.6 0.6
DDX43 32.4 2.1
TDRD12 27.3 5.3
UCP2 24.6 0.8
MGLL 18.4 0.6
CRIP1 15.5 1.1
RPL39L 13.4 1.4
CHODL 12.1 1.2
MGMT 10.4 1.2
CYB5R2 8.5 0.9
CYP2R1 8.0 1.6
KRT7 7.6 0.6
PRKCH 6.0 0.6
MAPK13 6.0 0.8
CNTLN 5.8 1.2
CXCR7 5.7 0.4
CTSO 5.0 0.7
ST14 5.0 0.8
BST1 4.6 1.3
GREM2 4.5 0.9
DMRT1 4.4 5.1
SLC7A4 3.9 1.3
LTBP2 2.8 0.4
KDELR3 2.6 0.6
PON3 2.5 2.3
C. Seminoma versus teratoma
Gene Noor (2015) Korkola et al.21
TACSTD2 438.9 0.0
DDX43 43.7 4.5
RBMXL2 42.8 2.2
ME1 35.4 0.5
RBM12B 21.9 1.2
QPCT 20.4 0.6
PRKCH 14.7 0.7
CAT 12.9 0.4
GALNT3 12.7 0.2
ECHDC2 8.9 0.6
PKP3 6.7 0.6
ST14 6.7 0.5
GREM2 4.9 0.5
SOX15 3.8 5.3
EDNRB 3.1 0.4
PON3 2.9 1.6
CYP1B1 2.5 0.3
EPS8L1 2.5 0.8
SULT1A1 2.5 1.0
LPHN3 2.3 0.7
VAV1 2.3 1.1
TEAD3 2.2 0.7
ELMO3 2.0 0.8
Abbreviations: EC, embryonal carcinoma; YST, yolk sac tumour.
The ‘fold change’ column is the fold change in expression seen
between the seminoma and non-seminoma cell lines in our study.
The ‘Korkola fold change’ and ‘Palmer fold change’ are the difference
in expression seen in primary tumours in the studies by Korkola et al.21
and Palmer et al.22 Only genes for which data were available in all
data sets are shown. Genes where expression in seminoma cells
is at least 1.5-fold greater than in the non-seminoma cells are
in bold.
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Among the other genes identiﬁed, several have particular roles
during male gamete production. DDX43 and TDRD12 were
speciﬁcally hypomethylated in seminoma cells. DDX43 encodes
a ‘cancer testis antigen’ (also called HAGE), which is an
RNA-dependent helicase with expression largely restricted to
testis and a variety of cancer types.40 TDRD12 encodes a tudor
domain-containing protein (also capable of functioning as an
RNA-dependent helicase) found almost exclusively in testes.41 It is
important in the biogenesis of piRNAs, which are also testis
speciﬁc.41 Hence the heavy methylation of these genes in all
control samples is consistent with their very restricted expression
patterns in normal tissues. This implies that the difference in
expression of these two genes between GCT subtypes is due to
hypomethylation in seminoma (and teratoma for TDRD12). MNS1
and RBMXL2 on the other hand were hypermethylated in
YST cells. MNS1 (meiosis-speciﬁc nuclear structural 1) encodes a
coiled-coil protein of unknown function, which is essential for
spermiogenesis.42 RBMXL2 (also called hnRNP G-T) codes for an
hnRNP expressed almost exclusively in testes and GCTs believed
to function during meiotic prophase or to act as a germ cell-
speciﬁc splicing regulator.43 Hence, the silencing of these genes in
non-seminomas may also play a role in their differentiation
towards somatic cell lineages.
PRDM14
PRDM14, which is differentially methylated and expressed
between the seminoma and YST cell lines (methylated and
silenced in YST), merits special attention. It encodes a multiple zinc
ﬁnger transcription factor almost exclusively expressed in PGCs,
GCTs and blastocyst stage embryos (NCBI EST proﬁle http://www.
ncbi.nlm.nih.gov/IniGene/ESTProﬁleViewer.cgi?uglist =Hs.287532),
which can function as both an activator and repressor of
transcription and may possess DNA methyltransferase activity.
Alongside PRDM1 (BLIMP1), PRDM14 activates TFAP2c (which
encodes AP2γ) and together these three ‘key regulators of PGC
speciﬁcation’44–46 repress somatic gene expression, activate PGC
genes and initiate the demethylation of the genome. Together
these factors can convert ES cells to PGCs.44–46 PRDM14 actively
promotes DNA demethylation by directly repressing the DNA
methytransferases, DNMT3a, DNMT3b, DNMT3l and UHRF1
(a DNMT1 cofactor)38,47,48 and directly activating DNA demethyla-
tion by increasing the activity of the TET enzymes.48
In mice, Prdm14 can also enhance reprogramming of somatic
cells to iPS cells by Sox2, Oct4 and Klf4.49 It regulates Oct449 and
can even induce pluripotency when overexpressed alongside
Blimp1 and Prmt5.50
Increased copy number of the PRDM14 gene has been reported
in GCTs51 and a recent GWAS study identiﬁed PRDM14 as a
susceptibility locus in testicular cancer.52 Studies in normal ES cells
(where PRDM14 is also expressed but at much lower levels than in
PGCs) provide evidence for a role in the progression of GCTs
towards the YST phenotype. In one study, knockdown of PRDM14
led to differentiation towards extraembryonic endoderm,47
a tissue type similar to that seen in YSTs. However, this remains
somewhat contentious since, in a similar study by others,
knockdown of PRDM14 caused cells to differentiate into
embryonic cell types.53
Together, these data suggest that PRDM14 could play a central
role in GCT progression in which it is initially expressed in
seminomas hence helping to retain their germ cell-like phenotype.
It is then silenced by methylation triggering more widespread
methylation of the genome and promoting the cells’ differentia-
tion into the extraembryonic cell types that typify YSTs.
Conclusions
This study revealed a very different methylator phenotype in
non-seminoma cell lines as compared with other types of cancer.
Several new potentially biologically important genes were
identiﬁed, most particularly a group of genes associated with
the germ cell state and/or pluripotency—PRDM14, TDRD12,
DDX43, MNS1, RBMXL2 and Klf4. Silencing of these factors that
normally suppress somatic differentiation could be a mandatory
step in the progression from seminoma to non-seminoma. Both
the silenced genes and gene methylation generally represent new
potential therapeutic targets for the more chemoresistant GCTs.
MATERIALS AND METHODS
Cell culture and 5-deoxyazacytidine treatment
Adult GCT cell lines were TCAM2 (seminoma54,55), GCT27 (EC56), NT2D1
(teratoma56) and GCT44 (YST57).
These were cultured in Dulbecco’s Modiﬁed Eagle Medium (EC, teratoma
and YST) and RPMI-1640 media (seminoma) (Sigma-Aldrich, Dorset, UK)
containing 10% foetal bovine serum (Sigma-Aldrich) and 1% penicillin/
streptomycin (Sigma-Aldrich). For demethylation experiments 1 × 105
YST cells were treated with 5 μM 5-deoxyazacytidine (Sigma). After 24 h,
medium was replaced with a fresh medium without 5-deoxyazacytidine
then cells were left for one further day. Cells were then trypsinized for
expression analysis.
Methylation analysis
Bisulﬁte conversion of the DNA (1 μg) was performed using EZ
DNA methylation kit (Zymo Research Corporation, Irvine, CA, USA), with
hybridisation to the Inﬁnium HumanMethylome450 arrays (Illumina, San
Diego, CA, USA) and scanning performed by the Queen Mary University of
London Genome Centre. Quality control of the dataset was performed by
analysing the bisulﬁte conversion using Genome Studio software
(Illumina). The ratio of unmethylated probe to methylated probe was
calculated with samples all showing good conversion rations o0.2. Low
signal intensity was also controlled for by removing CpG probes with an
averaged detection P value of40.05 across samples. In addition, averaged
signal intensity values for each CpG, for both the red and green signals,
across the samples were log2 transformed with values o11.1 removed.
For the analysis shown here, probes that bound multiple sites (chr-MULTI)
were excluded.
CpGs were annotated by the chip manufacturers according their
position relative to CpG islands: 2,000 bp either side of an island as north
‘shore’ (5′ relative to the associated gene) or south shore (3’ relative to the
associated gene). North and south ‘shelves’ 2,000 bp ﬂanking the shores,
and ‘other’ or ‘open sea’ for CpGs more distant from an island.’
Quantitative measurements of DNA methylation across all known genes
and CpGs were represented as β-values (0oβo1, 0 represents
unmethylated sites, and 1 indicates the site is fully methylated). Δβ-values
of differential methylation were calculated as the difference between the
β-values of each cell line relative to the seminoma cell line. The Excel tool
PivotTable (Microsoft ofﬁce 2010) was used to assign average methylation
and differential methylation measurements to each gene according to
various combinations of locations with respect to CpG islands and gene
regions. Probes labelled by multiple gene names were excluded from the
analysis.
For comparison of normal tissue against subset of CpG probes,
Marmal-aid software was utilised58 with clustering using R program
‘fast cluster’ (www.bioconductor.org). Normal tissue included 4 prostate
samples (GEO accession GSE38240—sample identiﬁers GSM937263,
GSM937265, GSM937267 and GSM937269), 5 blood samples
(GSE41169—sample identiﬁers GSM1009666, GSM1009667, GSM1009668,
GSM1009686 and GSM1009688) and 12 blood samples from Heyn et al., 59
(4 new born—CB15, CB76, CB23 and CB9; 5 adult—MA1, MA16, A29, A30
and A31 and 3 adults 480 years old—OLD16, OLD17 and OLD18).
Hierarchical clustering of probes within CpG islands were performed using
ward’s method, with β-values represented as heatmaps.
Expression array analysis
RNA extraction was performed using the RNeasy extraction kit (Qiagen,
Manchester, UK) according to the manufacturer's protocol. RNA was eluted
with RNAse-free water (Qiagen). The quality of TGCT RNA samples was
determined using a Bioanalyzer 2100 (Agilent Technologies, Santa Clara,
CA, USA) as suggested by the manufacturer. Measurement was calculated
using 2100 expert software version B.02.07 (Agilent Technologies) and
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displayed as RNA concentration, the ribosomal ratio and the RNA integrity
number (RIN). For the purpose of selecting samples for Affymetrix Gene
Expression array, samples with RIN49.0 were selected as this implies a
high-quality RNA sample. Arrays were performed at the Nottingham
Arabidopsis Stock Centre, University of Nottingham Sutton Bonington
Campus using Affymetrix GeneChip Human Genome U133 Plus 2.0 arrays
(the University of Nottingham).
Data were ﬁrst preprocessed using the statistical software, R with ‘Affy’
package provided by www.bioconductor.org. Data were normalised using
the RMA method60 and ﬁltered such that probes which gave expression
outputs below control background probes (recorded in the GeneChip) for
all four cell lines were excluded. Fold changes in expression between each
probe of each cell lines relative to Seminoma were calculated, and
annotation packages were used to assign gene information to each probe
set. The data were exported as a.txt ﬁle to be read and analysed in Excel.
The Excel tool PivotTable was used to assign average expression intensity
values to each gene.
CEL ﬁles from the studies by Palmer et al.22 and van der Zwan et al.18
were processed using the statistical package, R. Data were normalised
using the RMA method, and ﬁltered to exclude outputs that fell below
background levels. These data were then processed in Excel and a one-
tailed (right tail) Welch’s t-test was performed for each gene comparing
Seminoma samples with non-seminoma samples (P value of o0.05
indicated signiﬁcantly higher expression in seminoma samples versus YST
samples).
RT–PCR and RT–qPCR
RNA was extracted in TRI Reagent (Sigma) and treated with DNAse
(Invitrogen, Paisley, UK). Complementary DNA was synthesised using
random primer mix (Promega, Southampton, UK) and 200 ng of Oligo(dT)
18 Primer (Fermentase Hanover, NH, USA) and reverse transcriptase
(Invitrogen). PCR was carried out using Phusion High-Fidelity PCR Master
Mix (NEB, Herts, UK).
For RT–qPCR, a master mix for each primer pair was prepared by mixing
2X Brilliant SYBR Green QPCR Master Mix (Agilent), 100 nM of forward and
reverse primer, and water up to 25ml/well. About 25 μl of master mix was
transferred into each designated well of a 96-well plate before adding
50 ng complementary DNA into each well. Samples were then subjected to
PCR using Bio-Rad C1000 Thermal Cycler machine (Bio Rad, Heatfords, UK).
The PCR cycling condition are as follows: 95 °C for 3 min followed by 35
cycles of 95 °C for 1 min, 58 °C for 1 min and 72 °C for 30 s then 72 °C for
5 min. All data were then analysed using Bio-Rad CFX Manager 3.0 software
(Bio Rad).
The threshold cycle (Ct) values of each sample was deﬁned by standard
threshold and the relative comparison with the housekeeping gene, ACTB,
was calculated using the Pfafﬂ equation.61
No ethical approval was required for this study.
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